Low treatment initiation rates among multidrug-resistant tuberculosis patients in Gauteng, South Africa, 2011

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 8, 2013, Pages 1043-1048

  Ebonwu, Joy I ^a,b   Tint, K S ^a,b   Ihekweazu, C ^c,d  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

^c NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Death; MDR TB transmission; Patient tracing; Risk markers; Untreated patients

Indexed keywords

ADULT; AGED; ARTICLE; BACTERIAL TRANSMISSION; CHILD; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY DIAGNOSIS; LAND USE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIXED INFECTION; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; NEGRO; PATIENT REFERRAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SOUTH AFRICA; TREATMENT DURATION; TREATMENT REFUSAL; UNEMPLOYMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REFERRAL AND CONSULTATION; RISK FACTORS; SOUTH AFRICA; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84880460520     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0071     Document Type: Article

References (23)

1. Weyer K, Van der Walt M, Kantor P. Managing multidrug- resistant tuberculosis: legal implications. Medical Research Council Policy Brief 2006. Cape Town, South Africa: SA MRC, 2006. http://www.mrc.ac.za/policybriefs/ managing TB.pdf Accessed May 2013.
2. Shin S S, Pasechnikov A D, Gelmanova I Y, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis 2007; 11: 1314-1320.
3. Cox H S, Kalon S, Allamuratova S, et al. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures. PLoS ONE 2007; 2: e1126.
4. Shean K P, Willcox P A, Siwendu S N, et al. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002. Int J Tuberc Lung Dis 2008; 12: 1182-1189.
5. Kliiman K, Altraja A. Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J 2009; 33: 1085-1094.
6. World Health Organization. Multidrug and extensively drugresistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3. Geneva, Switzerland: WHO, 2003.
7. National Department of Health. Multidrug-resistant tuberculosis: a policy framework on decentralized and deinstituitionalized management for South Africa. Pretoria, South Africa: National Department of Health, South Africa, 2011.
8. Koornhof H, Ihekweazu C, Erasmus L, Coetzee G. Update on corporate data warehouse-derived MDR- and XDR-TB statistics for eight provinces in South Africa, January 2007 to 30th June 2011. Commun Dis Surveill Bull 2011; 9: 68-72.
9. Weyer K, Lancaster J, Brand J, Van der Walt M, Levin J. Survey of tuberculosis drug resistance in South Africa: 2001-2002. Cape Town, South Africa: Medical Research Council of South Africa, 2004.
10. National Department of Health. Management of drug- resistant tuberculosis: policy guidelines. Pretoria, South Africa: National Department of Health, South Africa, 2011.
11. Yimer S, Bjune G, Alene G. Diagnostic and treatment delay among pulmonary tuberculosis patients in Ethiopia: a cross sectional study. BMC Infect Dis 2005; 5: 112.
12. Chern J P, Chen D R, Wen T H. Delayed treatment of diagnosed pulmonary tuberculosis in Taiwan. BMC Public Health 2008; 8: 236.
13. Farah M G, Rygh J H, Steen T W, Selmer R, Heldal E, Bjune G. Patient and health care system delays in the start of tuberculosis treatment in Norway. BMC Infect Dis 2006; 6: 33.
14. Narasimooloo R, Ross A. Delay in commencing treatment for MDR TB at a specialised TB treatment centre in KwaZulu- Natal. S Afr Med J 2012; 102: 360-362.
15. Loveday M, Wallengren K, Voce A, et al. Comparing early treatment outcomes of MDR-TB in decentralised and centralised settings in KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 2012; 16: 209-215.
16. World Health Organization. South African tuberculosis profile 2011. Geneva, Switzerland: WHO, 2011. http://www.who.int/tb/data Accessed May 2013.
17. Golub J E, Bur S, Cronin W A, et al. Delayed tuberculosis diagnosis and tuberculosis transmission. Int J Tuberc Lung Dis 2006; 10: 24-30. (Pubitemid 43266273)
18. Meintjes G, Schoeman H, Morroni C, Wilson D, Maartens G. Patient and provider delay in tuberculosis suspects from communities with a high HIV prevalence in South Africa: a crosssectional study. BMC Infect Dis 2008; 8: 72.
19. Lee C H, Lee M C, Lin H H, et al. Pulmonary tuberculosis and delay in anti-tuberculous treatment are important risk factors for chronic obstructive pulmonary disease. PLoS ONE 2012; 7: e37978.
20. Cain K P, Anekthananon T, Burapat C, et al. Causes of death in HIV-infected persons who have tuberculosis, Thailand. Emerg Infect Dis 2009; 15: 258-264.
21. Médecins Sans Frontières. Scaling up diagnosis and treatment of drug-resistant tuberculosis in Khayelitsha, South Africa: an integrated, community-based approach, March 2011. Bloemfontein, South Africa: MSF, 2011. http://www.msf.org. za/publication/scaling-diagnosis-and-treatment- drug-resistant-tuberculosis- khayelitsha-south-africa Accessed May 2013.
22. Brust J C M, Gandhi N R, Carrara H, Osburn G, Padayatchi N. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003. Int J Tuberc Lung Dis 2010; 14: 413- 419.
23. Shenoi S, Heysell S, Moll A, Friedland G. Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community. Curr Opin Infect Dis 2009; 22: 11-17.